Biopsy

A new research perspective was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Crossroads: the role of biomarkers in the management of lumps in the breast.”

Here, Dr. Georg F. Weber from the University of Cincinnati Academic Health Center discusses a long-standing issue in women’s health: lumps in the breast. Women over the age of 40 years often have lumps in their breasts that are not cancerous at the time of biopsy (comprising atypias, hyperplasias, papillomas, radial scars, lobular carcinoma in situ, ductal carcinoma in situ (DCIS)). These premalignant lesions in the breast pose a difficult decision-making problem, whether to treat proactively and accept the side effects or to engage in watchful waiting and possibly encounter a later diagnosis of invasive cancer. 

These patients need to make the difficult decision whether to treat the lesions proactively and accept the substantial compromise in their quality of life (from surgery, radiation, or hormone therapy: Surgery often ensues for definitive diagnosis. Radiation may follow the surgical resection of DCIS by lumpectomy. Hormone therapy can come into play as a strategy for risk reduction if the estimated 5-year risk exceeds 1.6% in the Gail model [2]) or to engage in watchful waiting and risk a later diagnosis of invasive cancer (the proverbial sword of Damocles). Currently, two forms of assessment are available to facilitate making that choice.

Decades of cancer diagnosis and treatment have achieved substantial improvements. Yet, with every milestone of progress, new needs have surfaced. Breast care is privileged to have the availability of mammography and biopsy to assess the propensities of lumps. 

“A meaningful next step needs to entail biomarker development, pointing the way toward either preemptive treatment or watchful waiting at the crossroad.”

DOI: https://doi.org/10.18632/oncotarget.28402

Correspondence to - Georg F. Weber - georg.weber@uc.edu

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28402

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - breast cancer premalignant lesion, biomarker, biopsy, mammography

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, describes a research perspective he authored that was published by Oncotarget in Volume 14, entitled, “Crossroads: the role of biomarkers in the management of lumps in the breast.”

DOI - https://doi.org/10.18632/oncotarget.28402

Correspondence to - Georg F. Weber - georg.weber@uc.edu

Abstract

Premalignant lesions in the breast pose a difficult decision-making problem, whether to treat proactively and accept the side effects or to engage in watchful waiting and possibly encounter a later diagnosis of invasive cancer. A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system. The gene products of tumor progression may be expressed in early non-cancerous (“premalignant”) lesions, where they are associated with a high probability for full transformation in breast cancers. One such molecule is the OPN splice variant-c. OPN-c is also present in a fraction of the premalignant lesions, where it reflects an elevated risk for progression to cancer within 5 years, regardless of the lesion’s subtype. This marker has the properties needed to facilitate decisions to treat at the premalignant stage.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28402

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - breast cancer premalignant lesion, biomarker, biopsy, mammography

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Role of Biomarkers in Management of Lumps in the Breast

https://www.centerforadvancedwoundcare.com/understanding-the-benefits-of-a-comprehensive-wound-biopsy-in-chronic-wound-treatment/


A wound biopsy provides you with an accurate diagnosis and helps inform an effective treatment plan. In this article, we’ll discuss what a wound biopsy is, how it can help manage chronic wounds, and why it’s an important tool in your journey towards healing. We’ll also provide some tips on how to make the most out of your biopsy results. By the end, you’ll have a complete understanding of the benefits of a comprehensive wound biopsy in chronic wound treatment.

Understanding The Benefits Of A Comprehensive Wound Biopsy In Chronic Wound Treatment

In this Wound Care Q & A, Drs. Tickner and Suzuki talk about the role of biopsy and key considerations for clinicians to keep in mind.

Biopsy in Wound Care

During this episode, Barnaby Pickering is joined by Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis, Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung cancer, and Lishan Aklog, CEO of Lucid Diagnostics, who have developed a cell-collection method that aims to bring forward the stage at which oesophageal cancer can be diagnosed.

The group discuss the companies’ products and why they are transformative, as well as the upcoming regulatory and commercial hurdles awaiting diagnostics companies.

Trio Of Diagnostics Execs Weigh In On Upcoming Challenges

https://healthcheckbox.com/gynecology/breast-biopsy/

Borsbiopsie
'n Borsbiopsie is 'n prosedure wat 'n weefselmonster uit die bors verwyder om na kanker of ander abnormaliteite te kyk. 
Types of Borsbiopsie
Soorte Borsbiopsie
 Fine Needle Biopsy:
Fynnaald aspirasie biopsie. Dit is die eenvoudigste tipe borsbiopsie en kan gebruik word om 'n knop wat tydens 'n kliniese borsondersoek gevoel kan word, te evalueer. Vir die prosedure lê jy op 'n tafel. Terwyl jy die knop met een hand vasmaak, gebruik jou dokter die ander hand om 'n baie dun naald in die knop te rig.
Core Needle biopsy:
Kernnaaldbiopsie. Hierdie tipe borsbiopsie kan gebruik word om 'n borsknop te bepaal wat sigbaar is op 'n mammogram of ultraklank of wat jou dokter tydens 'n kliniese borsondersoek voel. 'n Radioloog of chirurg gebruik 'n dun, hol naald om weefselmonsters uit die borsmassa te verwyder, meestal met behulp van ultraklank as 'n riglyn.
Stereotatic biopsy
Stereotaktiese biopsie. Hierdie tipe biopsie gebruik mammogramme om die ligging van verdagte areas binne die bors vas te stel.
Ultrassound-Guided Core needle biopsy
Ultraklankgeleide kernnaaldbiopsie. Hierdie tipe kernnaaldbiopsie behels ultraklank - 'n beeldmetode wat hoëfrekwensie klankgolwe gebruik om presiese beelde van strukture binne die liggaam te produseer.
MRI-Guided Core needle biopsy
MRI-geleide kernnaaldbiopsie. Hierdie tipe kernnaaldbiopsie word onder leiding van 'n MRI gedoen - 'n beeldtegniek wat veelvuldige deursneebeelde van die bors vasvang en dit kombineer, met behulp van 'n rekenaar, om gedetailleerde 3D-prente te genereer.

Breast Biopsy(Borsbiopsie)

https://healthcheckbox.com/gynecology/cervical-biopsy/

Cervical Biopsy
'n Servikale biopsie is 'n prosedure om weefsel uit die serviks te verwyder om te toets vir abnormale of voorkankertoestande, of servikale kanker.
Die serviks is die onderste, smal deel van die baarmoeder. Dit vorm 'n kanaal wat in die vagina oopmaak.
Servikale biopsies kan op verskeie maniere gedoen word. Die biopsie kan 'n weefselmonster vir toetsing verwyder. Dit kan ook gebruik word om abnormale weefsel heeltemal uit te haal. Dit kan ook selle behandel wat in kanker kan verander.
Tipes 
Punch biopsie. Hierdie prosedure gebruik 'n sirkelvormige lem, soos 'n papiergatponser, om 'n weefselmonster te verwyder. Een of meer ponsbiopsies kan op verskillende areas van die serviks gedoen word.
Kegelbiopsie. Hierdie prosedure gebruik 'n laser, elektriese lus of skalpel om 'n groot keëlvormige stuk weefsel uit die serviks te verwyder.
Endoservikale curettage (ECC). Hierdie prosedure gebruik 'n smal instrument wat 'n curette genoem word om die voering van die endoservikale kanaal te skraap. Dit is 'n area wat nie van die buitekant van die serviks gesien kan word nie.
Voorsorgmaatreël
Gebruik sanitêre handdoeke in plaas van tampons 
Stort in plaas van om te bad 
Vermy seksuele omgang 
Vermy swembaddens/warmbaddens 
Vermy strawwe oefening soos aerobics-klasse, hardloop, gevegskuns 
Vermy oorsese reise vir 7 dae 
Beperk aktiwiteit vir 'n paar daz

Cervical Biopsy(Servikale biopsie)

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Podiatry Today Podcasts brings you the latest in foot and ankle medicine and surgery from leaders in the field.

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

New tracks tagged #BioPsy